Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of irinotecan, cisplatin and mitomycin C for advanced kidney cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a combination of the chemotherapy drugs irinotecan, cisplatin and mitomycin C (IPM) for advanced kidney cancer. Advanced kidney cancer means the cancer has spread from where it first developed in the kidney.
More about this trial
Doctors often use biological therapy to treat advanced kidney cancer. It can work well for some people, but researchers are looking for other treatments that may help if the cancer continues to grow.
In this trial they wanted to find out if a combination of 3 chemotherapy drugs called irinotecan, cisplatin and mitomycin C (IPM) can help people with advanced kidney cancer.
The aims of the trial were to
- See if kidney cancer responds to IPM chemotherapy
- Find out if it helps people to live longer
- Learn more about the side effects
Summary of results
The trial team found that using the combination of irinotecan, cisplatin and mitomycin C (IPM) did not improve the outlook for people with advanced kidney cancer. The team did not think it was any better than other treatments that are available.
In total 17 people took part in the trial. Everybody had IPM. On average people on the trial lived for 5 months. During the trial
- 1 person’s cancer shrunk slightly (
- 13 people’s cancer continued to grow despite treatment (progressive disease)
- 3 people died
The side effects from IPM were acceptable. The most common side effect was tiredness and weakness. Other side effects included infection and breathlessness (although the team though the breathlessness could also have been caused by the cancer).
So even though chemotherapy with IPM was well tolerated it did not improve the length of time people with advanced kidney cancer lived.
We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Dr Jonathan Shamash
Barts Health NHS Trust
Experimental Cancer Medicine Centre (ECMC)
Orchid Cancer Appeal